D. E. Shaw & Co., Inc. Novo Nordisk A S Call Options Transaction History

D. E. Shaw & Co., Inc.

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$119.07 - $145.42 $14.2 Million - $17.3 Million	-119,000 Reduced 56.8%	90,500 $10.8 Million
Q2 2024 Aug 14, 2024	BUY	$122.71 - $146.91 $22.9 Million - $27.4 Million	186,500 Added 810.87%	209,500 $29.9 Million
Q1 2024 May 15, 2024	SELL	$102.11 - $135.92 $1.17 Million - $1.56 Million	-11,500 Reduced 33.33%	23,000 $2.95 Million
Q4 2023 Feb 14, 2024	BUY	$87.78 - $105.45 $2.73 Million - $3.28 Million	31,100 Added 914.71%	34,500 $3.57 Million
Q3 2023 Nov 14, 2023	BUY	$90.94 - $199.54 $154,598 - $339,218	1,700 Added 100.0%	3,400 $309,000
Q2 2023 Aug 14, 2023	BUY	$155.98 - $172.65 $265,166 - $293,505	1,700 New	1,700 $275,000

1,957

320M

5.49M

7.78M

Ticker NVO
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 2,257,289,984
Market Cap $233B
Description
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.